Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia (DIREMOS)

Continuous, Real-time, Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia: Discharge Remote Monitoring System (DIREMOS)

Patients who have experienced dysglycemia in hospital (either from diabetes, post-solid organ transplantation, medication titration, or other causes) may struggle to manage their blood glucose when discharged home. This may lead to ER visits or readmissions that could have been prevented if glucose variations were detected before reaching extremes, and the variations were contextualized with other vital sign parameters. Remote monitoring via Dexcom G6 and Current Health (vital signs) used concomitantly after discharged for the purpose of remote monitoring will be evaluated with respect to ER visits and readmissions while considering the impact and usability of the potential integrated system on the healthcare staff.

Study Overview

• Status: Completed
• Conditions: Dysglycemia
• Intervention / Treatment: Device: Dexcom G6 CGM

Detailed Description

This is a single-site, open label, non-randomized, pilot and feasibility study. Participants will include post-hospitalized patients who experienced inpatient dysglycemia that required management from the endocrine service (including those newly diagnosed with T1 or T2 diabetes solid organ transplantation, COPD, post respiratory infections (i.e. COVID-19), chemo patients. Approximately 40 participants will be enrolled and assigned to receive the study intervention of real time-remote monitoring (rt-RM) using the Dexcom and Current Health integrated solution.

Potential participants will be identified via the EMR by the Endocrine Team and consented prior to enrollment, 2-48 hours prior to discharge. The study team will issue them Current Health and Dexcom CGM kits and provide the necessary training. Once discharged, the patients will be monitored by the endocrine team via routine "dashboard rounds" during working hours (8AM-5PM). Outside of dashboard rounds, management will be by exception, based on platform alarms directed to the endocrinology service. Alarms will be triaged and actioned according to pre-agreed protocols, including escalation to the appropriate specialists (endocrinologist, transplant surgeon, oncologist, pneumonologist, infectious disease specialist etc.). Participants will remain enrolled in the trial until either of the two endpoints: ER visits/ readmission or 30 days post discharge.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10029
      • Mount Sinai School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adults ≥21 years old
2. Treated for dysglycemia while in the acute (inpatient) period

3. With or without diabetes including patients with the following:

   • newly diagnosed T2D or T1D (LADA or other late onset)
   • post solid organ transplant
   • receiving or had received chemotherapy
   • COPD
   • Respiratory infections
4. Fit for discharge home in the opinion of the primary treating clinical team
5. Able to ambulate, or complete activities of daily living appropriate to their social care setting either on their own or with support

Exclusion Criteria:

1. Acute delirium or any other psychiatric condition that will not allow the person to participate
2. Current bleeding disorder
3. Lack of appropriate sites for CGM sensor or Current Health placement (sites must be free of large scars, skin irritation, surgical wounds, dressings, burns, anasarca, heavy tattooing etc.)
4. Any skin condition that prevents the use of CGM with adhesive
5. Known current pregnancy, breast feeding, or plan to become pregnant in the next 30 days
6. Unwilling to remove study devices prior to planned MRI and/or CT scan and reapply and wear after procedure(s) has completed.
7. Persistent atrial fibrillation
8. No access to home internet, cellular service or mobile telephone
9. Unwilling to use a study provided commercially available smartphone. The smartphones will be modified so they are only capable of hosting and running the study applications required for data collection. The modified smartphones will not be able to execute standard smartphone functionality such as internet browsing, texting, or making phone calls. Bluetooth functionality will remain intact as it is required for the approved applications to collect data.
10. Any other condition that, based on Investigator's judgment, would render the patient unsuitable to take part in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Study Criteria Met; Participants will be provided continuous vitals and glucose monitors at hospital discharge for their treating physician to have access to the data to review	Device: Dexcom G6 CGM; Once discharged, the patients will be monitored by the endocrine team via routine "dashboard rounds" during working hours (8AM-5PM). Outside of dashboard rounds, management will be by exception, based on platform alarms directed to the endocrinology service.; Other Names: Current Health Monitoring System

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduce amount of ER readmission in first 30 days after discharge	Number of participants with ER visits or readmissions as assessed by the evaluation of real time-remote monitoring (rt-RM) of blood glucose and vital signs after hospital discharge on unplanned service utilization	30 days
Pilot study satisfaction survey	Questionnaire or provided summary to evaluate patient and provider satisfaction of the remote monitoring technology.	30 days or less per patient

Collaborators and Investigators

• Sponsor: DexCom, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2023
• Primary Completion (Actual): November 29, 2023
• Study Completion (Actual): June 24, 2024

Study Registration Dates

• First Submitted: February 7, 2023
• First Submitted That Met QC Criteria: February 23, 2023
• First Posted (Actual): February 27, 2023

Study Record Updates

• Last Update Posted (Estimated): November 25, 2025
• Last Update Submitted That Met QC Criteria: November 20, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: PTL-1000045

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No